Company Profile

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+3.58%	+2.96%

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
20/12/18	British shares falter as Fed, oil play Scrooge	RE
19/12/18	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
18/12/18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
17/12/18	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
07/12/18	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
05/12/18	FTSE : falls as growth angst spreads	RE
05/12/18	Growth and trade nerves grind European shares down to two-week low	RE
05/12/18	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
05/12/18	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
21/11/18	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
21/11/18	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

13/05/20	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
04/02/20	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
07/01/19	Shire : Form 8.3 - Takeda Pharmaceutical	PU
07/01/19	Shire : Form 8.3 -	PU
07/01/19	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

08/01/19	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
07/01/19	Les affaires reprennent dans la pharmacie
21/12/18	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18/12/18	Shire : plombé par le déclassement de Takeda
05/12/18	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

Shire PLC Stock Nasdaq

Stocks

SHPG

US82481R1068

Pharmaceuticals

Latest news : Shire PLC

Analysts' recommendations: Shire PLC

Press Releases: Shire PLC

News in other languages: Shire PLC

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHIRE PLC	-.--%	+3.58%	-	-	0
ELI LILLY AND COMPANY	-1.47%	-5.85%	+39.23%	+141.84%	992B
JOHNSON & JOHNSON	-2.51%	-4.33%	+51.26%	+38.91%	564B
ABBVIE INC.	-2.35%	-3.77%	+16.61%	+56.94%	391B
ROCHE HOLDING AG	-2.90%	+0.68%	+24.66%	+16.53%	330B
ASTRAZENECA PLC	-2.36%	-3.12%	+24.71%	+12.95%	280B
NOVARTIS AG	-2.45%	-2.88%	+24.29%	+29.93%	279B
NOVO NORDISK A/S	-1.91%	-0.87%	-41.95%	-48.26%	196B
AMGEN INC.	-1.74%	-5.09%	+16.02%	+47.00%	184B
GILEAD SCIENCES, INC.	-2.13%	-2.47%	+13.67%	+57.97%	156B
Average	-2.07%	+0.41%	+18.72%	+39.31%	374.58B
Weighted average by Cap.	-2.18%	-0.49%	+27.58%	+62.44%